Prescribing Nortriptyline

Why Nortriptyline Still Matters

The tricyclics are supposed to be dead. SSRIs buried them thirty years ago: safer in overdose, cleaner side-effect profiles, no blood levels to chase, no ECG to remember. For most patients, most of the time, that verdict is correct and you should reach for a first-line agent. But "rarely first-line" is not the same as "never useful," and the clinician who has retired the entire tricyclic class has quietly given up several things that nothing else in the formulary does as well.

Nortriptyline is the tricyclic you actually want to know how to use. It is a secondary amine, the active metabolite of amitriptyline, and that single fact drives everything good about it. Secondary amines shed most of the receptor promiscuity that makes tertiary tricyclics miserable: nortriptyline is among the least anticholinergic TCAs, the least likely to drop blood pressure and cause falls, and one of only three tricyclics with a genuinely actionable serum level. Where amitriptyline is a blunderbuss, nortriptyline is closer to a scalpel.

Its niches are real and they are underserved: melancholic depression (where TCAs outperform SSRIs), depression with chronic neuropathic pain (where a single drug treats both, with an NNT around 3 for the pain), treatment-resistant depression, and relapse prevention after ECT, where nortriptyline plus lithium is the gold-standard combination. When your melancholic, anhedonic, guilt-ridden, early-waking patient has failed two SSRIs, or your depressed patient also has diabetic neuropathy, or your patient just finished a course of ECT and you are terrified of the 80% six-month relapse rate, nortriptyline earns its place.

The thesis of this guide: nortriptyline is safe and effective when you respect three things: the U-shaped therapeutic window (50–150 ng/mL), the heart, and the overdose risk. Get a level, get an ECG in the patients who need one, don't hand a lethal quantity to an acutely suicidal patient, and titrate slowly. Do those four things and you have a precise, well-tolerated, level-guided antidepressant that treats populations the SSRIs leave behind.

Part 1: Indications: Who Is Nortriptyline For?

FDA-Approved Use

• Major depressive disorder (the primary, on-label indication)

The Evidence-Based Clinical Uses

Melancholic depression: the classic tricyclic advantage. This is where nortriptyline earns its keep. When depression takes the melancholic form (pervasive anhedonia, ruminating guilt, appetite and weight loss, early-morning awakening, prominent psychomotor change), tricyclics outperform SSRIs. When you lump all depressions together, TCAs and modern antidepressants come out roughly equal; it's the melancholic and severe subtypes where the tricyclic edge appears. If your patient has textbook melancholia and hasn't done well on serotonergic drugs, nortriptyline is a rational, evidence-supported move.

Depression with chronic neuropathic pain: two problems, one drug. Tricyclics relieve neuropathic pain independently of their antidepressant effect, at an NNT around 3, better than SSRIs (weaker/insufficient data) and comparable to or better than duloxetine (NNT ~5 for diabetic neuropathy). For the depressed patient who also has diabetic neuropathy, post-herpetic neuralgia, or another neuropathic syndrome, a single well-tolerated secondary amine can treat both. Nortriptyline is often preferred over amitriptyline here for tolerability, titrated toward 100–150 mg/day for the pain indication.

Treatment-resistant depression (as a switch or augmentation). Nortriptyline appears in the TRD algorithm as a switch option (it was one of the Step 3 choices in STAR*D, max 200 mg/day there) and as a noradrenergic augmenting agent added to an SSRI. A network meta-analysis of augmentation strategies put nortriptyline augmentation at RR ~2.05 (95% CI 1.02–4.11) vs placebo, a real signal, though from a small sample (n≈23) with a wide confidence interval. The mechanistic logic is sound: layer nortriptyline's noradrenergic action on top of an SSRI's serotonergic one. (See Part 7: this combination raises the tricyclic level and must be done carefully.)

Relapse prevention after ECT: a genuine gold standard. This is nortriptyline's signature role. Depression relapse after a successful ECT course is brutal: roughly 80–84% relapse within 6 months on placebo (in Sackeim's landmark 2001 trial, about 24 of 29 placebo patients relapsed). Continuation pharmacotherapy roughly halves that:

• Nortriptyline + lithium: ~35–40% relapse at 6 months (39% in Sackeim 2001, n=28)
• Nortriptyline alone: ~60% relapse at 6 months
• Placebo: ~80% relapse at 6 months

The nortriptyline-plus-lithium combination, two drugs you dose by blood level, became the reference standard for post-ECT continuation. Maintenance ECT alone performs about the same as nortriptyline + lithium (no statistical difference at 6 months), and combining maintenance ECT with pharmacotherapy beats either alone (~32% vs ~61% relapse at 1 year). If you are following patients out of an ECT course, this is the regimen to know.

Other supported, off-label roles:

• Migraine and tension-headache prophylaxis (amitriptyline has the longest track record; nortriptyline is better tolerated, a good pick for the depressed headache patient)
• Inflammatory depression: when hs-CRP is elevated (>1 mg/L), nortriptyline and bupropion appear to respond better than SSRIs
• Smoking cessation and ADHD: supported but not preferred; better tools exist for both

Worst Uses / Where Nortriptyline Does Not Belong

• Bipolar depression without a mood stabilizer: tricyclics rank near the top for inducing mania and mixed states
• Borderline personality disorder with impulsivity/suicidality: overdose lethality plus possible disinhibition/aggression
• The acutely suicidal patient with access to a large supply: overdose lethality (dispense small quantities or choose a safer agent)
• Recent MI (within ~6 months) or unstable cardiac / conduction disease
• Untreated narrow-angle glaucoma, significant urinary retention/BPH, uncontrolled seizure disorder: anticholinergic and seizure-threshold concerns

Part 2: Before You Start: Workup and Candidacy

Baseline Assessment

Routine baseline LFTs are not required (hepatotoxicity is vanishingly rare, ~4 per 100,000 patient-years); check them only if there's a clinical reason.

Who Is a Poor Candidate?

• Recent MI (<6 months), unstable angina, significant conduction disease or arrhythmia
• Acutely suicidal patients who can't be limited to small supplies
• Untreated narrow-angle glaucoma; significant urinary retention/BPH
• Uncontrolled seizure disorder
• Bipolar depression without a mood stabilizer
• Dementia/significant cognitive impairment (even the least-anticholinergic TCA is a liability here)

Part 3: How to Start and Dose

Formulation

Nortriptyline hydrochloride comes as capsules (10, 25, 50, 75 mg) and an oral solution (10 mg/5 mL). The liquid is useful for fine titration and for sensitive or elderly patients. All are generic and inexpensive.

Starting Dose and Titration

• Start: 25 mg at bedtime (10 mg in the elderly or the drug-sensitive).
• Titrate every 5–7 days as tolerated. Slow titration is the single biggest lever for tolerability: rushing produces anticholinergic and orthostatic side effects that drive patients off the drug.
• Depression target: typically 75–150 mg/day, guided by serum level rather than a fixed milligram number.
• Neuropathic pain: titrate toward 100–150 mg/day, held for at least ~2 weeks to judge the pain response.
• Elderly: start 10 mg, titrate more slowly, and expect a lower final dose.

Nortriptyline can be given once daily at bedtime (its sedation and any anticholinergic effects are then largely slept through), or split if a patient finds a single dose too sedating.

The Serum Level: Nortriptyline's Defining Feature

Nortriptyline is one of only three tricyclics (with imipramine and desipramine) that has a clinically validated, actionable serum level. And it is unique in the class for having a U-shaped ("therapeutic window") efficacy curve: it works best in a band and loses efficacy if the level is too low or too high.

Draw the level 8–12 hours after the last dose, at steady state (≥5–6 days at a stable dose / ≥5 half-lives).

The window matters because it inverts the usual intuition. With most drugs, no response means "go higher." With nortriptyline, a patient who stalls or deteriorates at a high dose may be above the window, and the fix is to come down. You cannot know this without a level.

Check a level: after reaching a target dose; whenever you add or stop a CYP-interacting drug; in any patient with a cardiac history; and in the TRD or polypharmacy setting, where metabolizer variability is wildest. Clinicians who run TRD clinics describe patients supratherapeutic on 75 mg and subtherapeutic on 200 mg: the same dose lands wildly differently across metabolizers, and only the level tells you where a given patient sits.

Part 4: Monitoring: The Schedule

Nortriptyline's monitoring is lighter than lithium's but centers on three things: the level, the heart, and anticholinergic/orthostatic tolerability.

Routine LFTs and other bloodwork are not needed absent a specific indication. There is no thyroid or renal monitoring burden as there is with lithium (though if you are running the nortriptyline + lithium post-ECT combination, the lithium brings its own full monitoring schedule).

Part 5: Side Effects and How to Manage Them

The governing principle: nortriptyline is the best-tolerated tricyclic, most of its side effects are dose- and level-dependent, and many ease over 2–4 weeks if the patient can get through the titration. Manage them early: as with any TCA, side effects, not lack of efficacy, are the usual reason patients quit. A high serum level is often the culprit; check one before assuming true intolerance.

Anticholinergic (Dry Mouth, Constipation, Urinary Retention, Blurred Vision)

Nortriptyline is the least anticholinergic tricyclic, but "least" is not "none," and these effects still appear, especially in the elderly.

Management

• Dry mouth: sugar-free gum/lozenges, frequent sips of water. Warn about dental decay over time.
• Constipation: fluids, fiber, stool softeners; escalate before it becomes obstruction. Severe, unmanaged constipation risks small-bowel obstruction in the elderly.
• Urinary retention: caution in BPH; watch for hesitancy/retention and the UTIs that follow.
• Blurred vision: usually tolerated and reassurable; can precipitate a crisis in narrow-angle glaucoma, screen for it first.
• Confusion/cognitive fog: more of an issue in older patients; anticholinergic burden is linked to increased dementia risk with chronic exposure. If it appears, lower the dose or reconsider the drug.
• If anticholinergic load is the problem and you must stay in-class, nortriptyline and desipramine are already the lowest-burden options: there's nowhere gentler to switch within the TCAs.

Cardiovascular (Orthostatic Hypotension, Tachycardia, Conduction Effects)

• Orthostatic hypotension / falls: driven by α1-blockade. Nortriptyline is the least orthostatic TCA, which is exactly why it's the tricyclic of choice for fall-prone and elderly patients. Still: start low, titrate slowly, check orthostatic vitals, and counsel slow position changes and adequate hydration.
• Heart rate / conduction: expect a modest resting heart-rate rise (~11%) and reduced heart-rate variability (~14%). Nortriptyline can prolong the QT and, via type 1A sodium-channel blockade, slow conduction. Get the baseline ECG in at-risk patients; repeat it if you push the dose substantially.
• Ischemic heart disease / recent MI: this is the real cardiac danger zone. In active ischemic disease the adverse-cardiac-event rate was markedly higher than with an SSRI (~18% vs ~2%). Avoid within 6 months of an MI and in unstable cardiac disease.

Sedation

Usually mild-to-moderate and often useful in the depressed patient with insomnia. Dose at bedtime. If daytime grogginess persists, lower the dose. Nortriptyline is less sedating than doxepin or amitriptyline.

Weight Gain

Real but generally less than the tertiary amines. Monitor weight; counsel on diet and activity; note that a lower effective dose (guided by the level) also limits it.

Sexual Dysfunction

A secondary-amine quirk worth counseling on: nortriptyline is less likely to cause anorgasmia than tertiary amines and SSRIs, but more likely to cause erectile dysfunction. Manage with dose/timing adjustment or, if it threatens adherence, targeted augmentation.

Seizure Threshold

Lowered, as with all TCAs. Caution in seizure-prone patients and in traumatic brain injury.

Hepatotoxicity

Extremely rare (~4 per 100,000 patient-years). No routine LFT monitoring needed.

Part 6: Overdose and Toxicity: The Non-Negotiable Safety Issue

This is the single most important safety fact about every tricyclic, nortriptyline included.

Why TCAs Are Dangerous in Overdose

Tricyclics exert type 1A antiarrhythmic (sodium-channel-blocking) effects on the heart. In overdose this produces widened QRS, conduction blocks, malignant arrhythmias, hypotension, seizures, and cardiovascular collapse. The class carries the highest overdose morbidity and mortality of any antidepressant group (in a National Poison Data System analysis, amitriptyline was among the two most dangerous of 48 antidepressants studied: morbidity index 345/1,000, mortality 3.8/1,000). Nortriptyline shares the class mechanism. A week's extra supply can be a lethal ingestion.

What This Means for Prescribing

• Match dispensing to risk. For any patient with meaningful suicide risk, dispense small quantities (a week or two at a time), enlist family to hold the medication, and reassess risk every visit.
• Prefer a safer agent (SSRI/SNRI) when the patient is acutely suicidal and there's no compelling tricyclic-specific indication.

Suicidality (Boxed Warning)

Part 7: Drug Interactions

Nortriptyline is metabolized hepatically (principally CYP2D6, with contributions from 2C19 and 1A2). The interactions that matter most are the ones that raise the nortriptyline level, because a level driven above the window costs efficacy and raises toxicity.

Drugs That Raise Nortriptyline Levels (CYP Inhibitors)

• Potent CYP2D6 inhibitors: fluoxetine and paroxetine. The classic offenders. Also bupropion, duloxetine, quinidine.
• Fluvoxamine (CYP1A2/2C19), cimetidine, and many others.
• Mechanism: reduced hepatic clearance leading to a rising tricyclic level and potential toxicity and loss of efficacy (over the top of the window).
• Management: when combining, start low, titrate slowly, and check a level: get a baseline nortriptyline level before adding the inhibitor, then recheck ~2 weeks later. This is precisely where nortriptyline's measurable level becomes a safety asset.

The "Safe" Antidepressant Partners (Minimal Effect on TCA Levels)

When you need a serotonergic partner without the CYP headache, these do not meaningfully raise tricyclic levels: citalopram, escitalopram, desvenlafaxine, mirtazapine, trazodone, vilazodone, vortioxetine.

Other Interactions to Respect

• MAOIs, contraindicated. The TCA + MAOI combination risks hypertensive crisis and serotonin syndrome. Observe the standard washout (typically ~2 weeks, longer after fluoxetine given its long half-life).
• Serotonin syndrome: possible with other serotonergic agents (lower risk than the more serotonergic clomipramine, but present); watch for agitation, tremor, hyperthermia, rigidity.
• Sympathomimetics (e.g., pseudoephedrine): risk of pressor effects.
• Additive anticholinergics / CNS depressants / alcohol: additive burden, review the whole med list.
• QT-prolonging drugs: additive QT risk; more caution and an ECG.

Part 8: Special Populations

Pregnancy

Nortriptyline is among the better-studied tricyclics in pregnancy and does not carry a specific major-malformation signal on the scale of, say, valproate. As always, weigh it against the substantial risks of untreated depression in pregnancy. Watch for neonatal adaptation/withdrawal (jitteriness, feeding issues, respiratory symptoms) with third-trimester exposure, and coordinate with obstetrics. Nortriptyline's measurable level is an advantage here: because clearance shifts across pregnancy, you can track the level and adjust the dose to keep the mother in the window rather than dosing blind.

Lactation

Nortriptyline is generally considered relatively compatible with breastfeeding among antidepressants; infant serum levels are typically low or undetectable. Monitor the infant for sedation and feeding, and coordinate with pediatrics. (When part of a post-ECT nortriptyline + lithium regimen, the lithium, not the nortriptyline, is the component that complicates breastfeeding decisions.)

Elderly

The core paradox: tricyclics are broadly discouraged in older adults (anticholinergic burden, falls, confusion, dementia-risk association), yet nortriptyline is the specific TCA you choose when a tricyclic is genuinely indicated in this group, because it is the least anticholinergic and least orthostatic. If you use it:

• Start 10 mg, titrate slowly, target a lower final dose.
• Baseline ECG and orthostatic vitals; recheck orthostatics as you titrate.
• Watch cognition, continence, bowels, and falls.
• Reserve it for clear indications (melancholic depression, neuropathic pain) rather than routine geriatric depression, where an SSRI is usually first.

Renal and Hepatic Impairment

• Hepatic: nortriptyline is cleared by the liver, use caution and reduce dose in significant hepatic impairment; the serum level is especially valuable for guiding dose here.
• Renal: no dramatic clearance-driven dose adjustment is mandated, but frail/renally impaired patients tolerate side effects less well, start low and lean on the level.

Children and Adolescents

Not a preferred agent (limited efficacy data for pediatric depression across TCAs; overdose lethality; the boxed suicidality warning is most pointed in the young). Not first-line for ADHD or smoking cessation either. Use, if at all, only with specialist involvement and careful risk management.

Part 9: Discontinuation

Tricyclics are generally easier to stop than the SNRIs (venlafaxine, duloxetine) or the short-half-life SSRIs (paroxetine, fluvoxamine), but "easier" is not "just stop."

• Taper gradually. Abrupt cessation can produce a cholinergic-rebound discontinuation syndrome (nausea, GI upset, malaise, sleep disturbance, sometimes a flu-like picture) and, more importantly, risks relapse of the underlying depression.
• Abrupt withdrawal has also been associated with withdrawal-emergent dyskinesias in the weeks after stopping.
• A slow taper over weeks, with a plan to resume promptly if depressive symptoms re-emerge, is the safe approach. As with any effective antidepressant, it is far easier to prevent a relapse than to re-treat a full episode.

Part 10: Nortriptyline vs the Alternatives

vs Amitriptyline (its parent tertiary amine). Same efficacy neighborhood, far better tolerability. Amitriptyline is the most anticholinergic and among the most orthostatic and most overdose-dangerous TCAs; nortriptyline is the least anticholinergic and least orthostatic. Amitriptyline has the longer pain/headache track record, but for most patients who need a tricyclic, nortriptyline is the better-tolerated way to get there.

vs Desipramine. The other secondary amine, similarly low in anticholinergic burden and also level-guided (target >125 ng/mL). Some clinicians prefer desipramine for its dosing flexibility: it lacks nortriptyline's upper efficacy ceiling, so you can push it without falling off a window. Nortriptyline's countervailing advantage is the best-validated, most-studied therapeutic window in the class. Reasonable clinicians choose between them by feel and by which level target they'd rather manage.

vs SSRIs. SSRIs win on overdose safety, cardiac safety, anticholinergic burden, and first-line simplicity, which is why they are first-line. Nortriptyline wins for melancholic depression, neuropathic-pain comorbidity, IBS-comorbid depression, and inflammatory depression (elevated CRP), and offers a measurable level. Choose the SSRI for the average patient; choose nortriptyline for the specific one.

vs SNRIs (duloxetine, venlafaxine). For neuropathic pain, tricyclics are at least as effective (NNT ~3 vs duloxetine's ~5) and cheaper, but SNRIs are far safer in overdose and better tolerated overall. For depression-plus-pain in a patient at low overdose risk, nortriptyline is a strong single-drug answer; the SNRIs are the safer default.

vs MAOIs. MAOIs are the escalation beyond tricyclics for atypical and truly refractory depression (a meaningful fraction of TCA non-responders respond to tranylcypromine). Different tier, different risk profile, and never co-administered with a TCA.

So why use nortriptyline at all, given SSRIs exist? Because for the melancholic patient, the patient in neuropathic pain, the post-ECT patient, and the SSRI/SNRI-resistant patient, it does something those drugs do less well, and it does it as the most tolerable, most measurable member of an otherwise blunt class.

Mechanism: The Short Version

Nortriptyline is the secondary-amine active metabolite of amitriptyline. Its primary antidepressant action is inhibition of norepinephrine reuptake (via the norepinephrine transporter), with only weak serotonin-reuptake activity, the reverse emphasis from the tertiary tricyclics, and the reason it's more "noradrenergic" and less serotonergic than amitriptyline. Being a secondary amine, it has shed much of the off-target receptor binding that makes tertiary TCAs miserable: it is comparatively weak at muscarinic (anticholinergic), α1-adrenergic (orthostatic), and H1-histaminergic (sedating) receptors, hence its cleaner profile.

The dark side of the same molecule is cardiac: like all tricyclics it exerts type 1A antiarrhythmic (fast sodium-channel-blocking) effects on cardiac conduction, which are benign at therapeutic levels in a healthy heart but are the mechanism of its lethality in overdose and its caution in cardiac disease. TCAs also downregulate β-adrenergic receptors over weeks (a classic correlate of the delayed antidepressant response) and have NMDA-modulating and descending-pain-pathway (serotonin/norepinephrine) effects that likely underlie the analgesic benefit running independent of mood.

The Bedside Cheat Sheet